Digital Content 
NEWS #PharmaBuzz
02 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250602107458/en/SERENA-6-Phase-III-Trial-Demonstrates-Clinical-Value-of-Guardant360-CDx-Test-to-Detect-Emergence-of-Endocrine-Resistance-and-Inform-a-Switch-in-Therapy-Before-Radiological-Disease-Progression-in-Advanced-Breast-Cancer
02 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250601316083/en/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial
01 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250601316083/en/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial
27 Feb 2025
// PRESS RELEASE
https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html
21 May 2024
// Nick Paul Taylor FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/astrazeneca-harness-chinas-explosion-innovation-boost-cell-therapy-rd
08 Dec 2022
// PRESS RELEASE
https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer.html
Share 